AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
dinoprostone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| prostaglandins | 913 | 363-24-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
The most common and most biologically active of the mammalian prostaglandins. It exhibits most biological activities characteristic of prostaglandins and has been used extensively as an oxytocic agent. The compound also displays a protective effect on the intestinal mucosa.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.50 | mg | O |
| 0.50 | mg | V |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 4.05 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,IKBKB,ITK,JAK2,JAK3,KDR,MAP2K6,MAP3K21,MAP3K7,MAPK7,MAPKAPK2,MTOR,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CG,PIM2,PLK1,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 | 48 | |||
| kinase-selectivity-class | AXL,BRAF,EIF2AK3,GRK2,MAP2K6 | 5 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 23, 2020 | PMDA | Ferring Pharmaceuticals Co., Ltd. | |
| Aug. 23, 1977 | FDA | PHARMACIA AND UPJOHN |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Uterine hyperstimulation | 349.27 | 72.36 | 36 | 1016 | 35 | 90627360 |
| Exposure during pregnancy | 194.81 | 72.36 | 80 | 972 | 238330 | 90389065 |
| Uterine hypertonus | 186.77 | 72.36 | 24 | 1028 | 297 | 90627098 |
| Uterine tachysystole | 154.85 | 72.36 | 16 | 1036 | 16 | 90627379 |
| Uterine rupture | 126.12 | 72.36 | 20 | 1032 | 1149 | 90626246 |
| Caesarean section | 118.70 | 72.36 | 30 | 1022 | 18547 | 90608848 |
| Postpartum haemorrhage | 105.17 | 72.36 | 19 | 1033 | 2382 | 90625013 |
| Anaphylactoid syndrome of pregnancy | 102.61 | 72.36 | 12 | 1040 | 62 | 90627333 |
| Meconium in amniotic fluid | 93.01 | 72.36 | 13 | 1039 | 311 | 90627084 |
| Maternal exposure during pregnancy | 89.56 | 72.36 | 54 | 998 | 360009 | 90267386 |
| Disseminated intravascular coagulation | 86.06 | 72.36 | 24 | 1028 | 21514 | 90605881 |
| Premature separation of placenta | 86.06 | 72.36 | 16 | 1036 | 2346 | 90625049 |
| Foetal anaemia | 77.16 | 72.36 | 10 | 1042 | 132 | 90627263 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Foetal exposure during pregnancy | 266.17 | 215.22 | 60 | 207 | 47251 | 42573817 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Exposure during pregnancy | 204.45 | 69.56 | 64 | 615 | 167360 | 110421260 |
| Uterine hyperstimulation | 158.96 | 69.56 | 16 | 663 | 31 | 110588589 |
| Uterine hypertonus | 157.50 | 69.56 | 19 | 660 | 271 | 110588349 |
| Caesarean section | 117.70 | 69.56 | 25 | 654 | 13792 | 110574828 |
| Meconium in amniotic fluid | 110.67 | 69.56 | 13 | 666 | 145 | 110588475 |
| Premature separation of placenta | 102.73 | 69.56 | 16 | 663 | 1564 | 110587056 |
| Uterine tachysystole | 102.66 | 69.56 | 10 | 669 | 11 | 110588609 |
| Maternal exposure during pregnancy | 92.32 | 69.56 | 40 | 639 | 254843 | 110333777 |
| Uterine rupture | 81.86 | 69.56 | 12 | 667 | 779 | 110587841 |
| Postpartum haemorrhage | 78.42 | 69.56 | 13 | 666 | 1876 | 110586744 |
| Anaphylactoid syndrome of pregnancy | 70.82 | 69.56 | 8 | 671 | 61 | 110588559 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | G02AD02 | GENITO URINARY SYSTEM AND SEX HORMONES OTHER GYNECOLOGICALS UTEROTONICS Prostaglandins |
| FDA CS | M0017805 | Prostaglandins |
| FDA EPC | N0000175454 | Prostaglandin Analog |
| MeSH PA | D010120 | Oxytocics |
| MeSH PA | D012102 | Reproductive Control Agents |
| CHEBI has role | CHEBI:35480 | analgesic |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:36063 | oxytocic |
| CHEBI has role | CHEBI:75771 | mouse metabolite |
| CHEBI has role | CHEBI:77746 | human metabolite |
Related Drugs by ATC class:
G02AD Prostaglandins 5 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Incomplete miscarriage | indication | 156072005 | |
| Induction of labor | indication | 236958009 | |
| Cervical ripening procedure | indication | 236959001 | |
| Pregnancy with abortive outcome | indication | 363681007 | |
| Hydatidiform mole, benign | indication | 417044008 | |
| Ocular hypertension | contraindication | 4210003 | DOID:9282 |
| Multiple pregnancy | contraindication | 16356006 | |
| Grand multipara | contraindication | 18656007 | |
| Disorder of lung | contraindication | 19829001 | DOID:850 |
| Glaucoma | contraindication | 23986001 | DOID:1686 |
| Disproportion between fetus and pelvis | contraindication | 25749005 | |
| Genital herpes simplex | contraindication | 33839006 | DOID:8704 |
| Placenta previa | contraindication | 36813001 | DOID:11060 |
| Inflammation of cervix | contraindication | 37610005 | DOID:2568 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Low blood pressure | contraindication | 45007003 | |
| Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
| Disseminated intravascular coagulation | contraindication | 67406007 | DOID:11247 |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Stenosis of cervix | contraindication | 83536006 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Uterine leiomyoma | contraindication | 95315005 | DOID:13223 |
| Female genital tract infection | contraindication | 125585007 | |
| Seizure disorder | contraindication | 128613002 | |
| Fetal distress | contraindication | 130955003 | |
| Spontaneous rupture of membranes | contraindication | 169734005 | |
| Asthma | contraindication | 195967001 | DOID:2841 |
| Deliveries by cesarean | contraindication | 200144004 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Abnormal uterine bleeding unrelated to menstrual cycle | contraindication | 312984006 | |
| Endocervical Lesions | contraindication | ||
| Uterine Hypertonic Patterns | contraindication | ||
| Gynecological Surgery | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.79 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Prostaglandin E2 receptor EP4 subtype | GPCR | AGONIST | Ki | 9.77 | CHEMBL | CHEMBL | |||
| Prostaglandin E2 receptor EP3 subtype | GPCR | AGONIST | Ki | 9.48 | CHEMBL | CHEMBL | |||
| Prostaglandin E2 receptor EP2 subtype | GPCR | AGONIST | Ki | 8.77 | CHEMBL | CHEMBL | |||
| Prostaglandin E2 receptor EP1 subtype | GPCR | AGONIST | Ki | 8.04 | CHEMBL | CHEMBL | |||
| Prostaglandin D2 receptor | GPCR | AGONIST | Ki | 7 | IUPHAR | ||||
| Prostaglandin F2-alpha receptor | GPCR | AGONIST | Ki | 6.90 | IUPHAR | ||||
| Cation channel sperm-associated protein 1 | Ion channel | ACTIVATOR | EC50 | 6.30 | IUPHAR | ||||
| Cation channel sperm-associated protein 2 | Ion channel | ACTIVATOR | EC50 | 6.30 | IUPHAR | ||||
| Cation channel sperm-associated protein 3 | Ion channel | ACTIVATOR | EC50 | 6.30 | IUPHAR | ||||
| Cation channel sperm-associated protein 4 | Ion channel | ACTIVATOR | EC50 | 6.30 | IUPHAR | ||||
| Prostaglandin D2 receptor 2 | GPCR | AGONIST | Ki | 5.30 | IUPHAR | ||||
| Prostacyclin receptor | GPCR | IC50 | 6.59 | CHEMBL | |||||
| Thromboxane A2 receptor | GPCR | AGONIST | Ki | 4.50 | IUPHAR | ||||
| Prostaglandin E2 receptor EP1 subtype | GPCR | Ki | 8.22 | CHEMBL | |||||
| Prostaglandin E2 receptor EP2 subtype | GPCR | Ki | 7.66 | CHEMBL | |||||
| Prostaglandin E2 receptor EP3 subtype | GPCR | Ki | 8.30 | CHEMBL | |||||
| Prostaglandin E2 receptor EP4 subtype | GPCR | Ki | 8.51 | CHEMBL | |||||
| Solute carrier family 22 member 6 | Transporter | Ki | 5.47 | CHEMBL | |||||
| Solute carrier family 22 member 20 | Transporter | Ki | 4.74 | CHEMBL | |||||
| Prostaglandin F2-alpha receptor | GPCR | AGONIST | Ki | 7 | IUPHAR | ||||
| Prostaglandin E2 receptor EP2 subtype | GPCR | IC50 | 8.28 | CHEMBL | |||||
| Prostaglandin E2 receptor EP4 subtype | GPCR | IC50 | 8.68 | CHEMBL | |||||
| Prostaglandin D2 receptor 2 | GPCR | AGONIST | Ki | 5.50 | IUPHAR | ||||
| Prostaglandin E2 receptor EP3 subtype | GPCR | AGONIST | EC50 | 9.39 | IUPHAR | ||||
| Prostaglandin E2 receptor EP1 subtype | GPCR | AGONIST | Ki | 7.70 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| 4018093 | VUID |
| N0000146431 | NUI |
| D00079 | KEGG_DRUG |
| 3478 | RXNORM |
| 4018093 | VANDF |
| C0012472 | UMLSCUI |
| CHEBI:15551 | CHEBI |
| P2E | PDB_CHEM_ID |
| CHEMBL548 | ChEMBL_ID |
| DB00917 | DRUGBANK_ID |
| D015232 | MESH_DESCRIPTOR_UI |
| 5280360 | PUBCHEM_CID |
| 3075 | INN_ID |
| K7Q1JQR04M | UNII |
| 4609 | MMSL |
| 001309 | NDDF |
| 387245009 | SNOMEDCT_US |
| 44798001 | SNOMEDCT_US |
| K7Q1JQR04M | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Prepidil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-3359 | GEL | 0.50 mg | VAGINAL | NDA | 20 sections |
| Prepidil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-3359 | GEL | 0.50 mg | VAGINAL | NDA | 20 sections |
| CERVIDIL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55566-2800 | INSERT | 10 mg | VAGINAL | NDA | 26 sections |